Terns Pharmaceuticals Inc... (TERN)
2.93
0.01 (0.34%)
At close: Apr 28, 2025, 1:15 PM
0.34% (1D)
| Bid | 2.92 |
| Market Cap | 255.78M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -88.85M |
| EPS (ttm) | -1.12 |
| PE Ratio (ttm) | -2.62 |
| Forward PE | -2.22 |
| Analyst | Buy |
| Ask | 2.93 |
| Volume | 234,148 |
| Avg. Volume (20D) | 1,293,849 |
| Open | 2.91 |
| Previous Close | 2.92 |
| Day's Range | 2.87 - 3.06 |
| 52-Week Range | 1.86 - 11.40 |
| Beta | -0.14 |
About TERN
Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis (NASH) and obesity. The company develops TERN-101, a liver-distributed and non-bile acid farnesoid X receptor agonist, which is in Phase IIa clinical trial for the treatment of NASH; and TERN-201, a vascular adhesion protein-1 inhibitor that is in Phase ...
Industry Biotechnology
Sector Healthcare
IPO Date Feb 5, 2021
Employees 59
Stock Exchange NASDAQ
Ticker Symbol TERN
Website https://www.ternspharma.com
Analyst Forecast
According to 5 analyst ratings, the average rating for TERN stock is "Buy." The 12-month stock price forecast is $20, which is an increase of 582.59% from the latest price.
Stock Forecasts1 month ago
+6.69%
Terns Pharmaceuticals shares are trading higher af...
Unlock content with
Pro Subscription
7 months ago
-4.9%
Terns Pharmaceuticals shares are trading lower after the company announced it priced a $150.1 million public offering of 11,919,048 shares at $10.50 per share.
